Drug-eluting particles in the treatment of HCC: chemoembolization with doxorubicin-loaded DC Bead™

References

• Llovet JM, Real MI, Montana X et al. Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet359, 1734–1731 (2002).
   PubMed Web of Science ®Google Scholar
• Lo CM, Ngan H, Tso WK et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology35, 1164–1161 (2002).
   PubMed Web of Science ®Google Scholar
• Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology37, 429–424 (2003).
   PubMed Web of Science ®Google Scholar
• Pelletier G, Ducreux M, Gay F et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. J. Hepatol.29, 129–121 (1998).
   PubMed Web of Science ®Google Scholar
• Gamma C Schepis F, Orlando A et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology224, 47–45 (2002).
   PubMedGoogle Scholar
• Bruix J, Sherman M, Llovet JM et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona–2000 EASL Conference. European Association for the Study of the Liver. J. Hepatol.35, 421–424 (2001).
   PubMed Web of Science ®Google Scholar
• Osuga K, Khankan AA,Hori S et al. Transarterial embolization for large hepatocellular carcinoma with use of superabsorbent polymer microspheres: initial experience. J. Vasc. Interv. Radiol.13, 929–929 (2002).
   PubMedGoogle Scholar
• Hori S, Okada A, Sakamoto K et al. A new embolic material: superabsorbent polymer microsphere and its embolic effects. Jpn. J. Intervent. Radiol.11, 375–373 (1996).
   Google Scholar
• Kankan AA, Osuga K, Hori S, Morii E, Murakami T, Nakamura H. Embolic effects of superabsorvent polymer midrospseres in rabbit renal model: comparison with tris-acryl gelatine microspheres and polyvinyl alcohol. Radiat. Medicine22, 384–383 (2004).
   PubMedGoogle Scholar
• Varela M, Real MI, Burrel M et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J. Hepatol.46(3), 474–481 (2007).
   PubMed Web of Science ®Google Scholar
• Malagari K, Chatzimichael K, Alexopoulou E et al. Transarterial chemoembolisation of unresectable hepatocellular carcinoma (HCC) with drug eluting beads (DEB); results of an open label study of 62 patients Presented at ECR 9–13 (2007). Cardiovasc. Intervent. Radiol.31(2), 269–280 (2008).
   PubMed Web of Science ®Google Scholar
• Malagari K, Alexopoulou E, Chatzimichail K et al. Transcatheter chemoembolization in the treatment of HCC in patients not eligible for curative treatments: midterm results of doxorubicin-loaded DC Bead. Abdom. Imaging33(5), 512–519 (2008).
   PubMed Web of Science ®Google Scholar
• Poon RN, Tso WK, Pang RWC et al. A Phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin. Gastroenterol. Hepatol.5, 1100–1101 (2007).
   PubMed Web of Science ®Google Scholar
• Hong K, Khwaja A, Liapi E et al. New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin. Cancer Res.12, 2563–2567 (2006).
   PubMed Web of Science ®Google Scholar
• Lewis AL, Gonzalez MV, Lloyd AW et al. DC Bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J. Vasc. Interv. Radiol.17, 335–334 (2006).
   PubMed Web of Science ®Google Scholar
• Lewis AL, Taylor RR, Hall B et al. Pharmacokinetic and safety study of doxorubicin-eluting beads in a porcine model of hepatic arterial embolization. J. Vasc. Interv. Radiol.17(8), 1335–1343 (2006).
   PubMed Web of Science ®Google Scholar
• Namur J, Wassef M, Millot J-M et al. Doxorubicin eluting beads for liver embolization: pathological findings and correlation with drug distribution in tissue. Presented at: 35th Annual Meeting and Exposition of the Controlled Release Society. NY, USA, 12–16 July 2008 (Abstract 109).
   Google Scholar
• Gonzalez MV, Tang Y, Philips GJ et al. Methods for evaluating drug elution and in vitro-in vivo correlation. J Mater. Sci. Mater. Med.19, 767–775 (2008).
   PubMed Web of Science ®Google Scholar
• Brown KT. Fatal pulmonary complications after arterial embolization with 40–120- micro m tris-acryl gelatine microspheres J. Vasc. Interv. Radiol.15(2 Pt 1), 197–200 (2004).
   PubMed Web of Science ®Google Scholar
• Barnett BP, Liapi E, Kim GK et al. PEGDA based spheres – chemospheres. Presented at: SIR Annual Meeting. DC, USA, 15–20 March 2008.
   Google Scholar
• Herber S, Pitton M, Mönch C et al. Transarterial chemoembolization (TACE) of the hepatocellular carcinoma (HCC) in patients with portal vein thrombosis – experiences. Zentralbl. Chir.132(4), 306–315 (2007).
   PubMedGoogle Scholar
• Raoul JL, Heresbach D, Bretagne JF. Chemoembolization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. Cancer70(3), 585–590 (1992).
   PubMed Web of Science ®Google Scholar
• Groupe D’Etude et de Traitment du Carcinome Hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N. Engl. J. Med.332, 1256–1261 (1995).
   PubMed Web of Science ®Google Scholar
• Malagari K, Pomoni M, Pomoni A et al. Long term results of doxorubicin-loaded DC Bead in the treatment of HCC survival, recurrence free interval and quality of life. Presented at: EASL Monothematic Liver Conference. Liver Cancer: From Molecular Pathogenesis to New Therapies. Prague, Czech Republic, 12–14 June 2008.
   Google Scholar
• Yuen MF, Chan AOO, Chun-Yu B et al. Transarterial chemoembolization for inoperable, early stage hepatocellular carcinoma in patients with Child–Pugh grade A and B: results of a comparative study in 96 Chinese patients. Am. J. Gastroenterol.98(5), 1181–1185 (2003).
   PubMed Web of Science ®Google Scholar
• Matsui O, Kadoya M, Yoshikawa J et al. Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization. Radiology188, 79–78 (1993).
   PubMed Web of Science ®Google Scholar
• Saccheri S, Lovaria A, Sangiovanni A et al. Segmental transcatheter arterial chemoembolization treatment in patients with cirrhosis and inoperable hepatocellular carcinomas. J. Vasc. Interv. Radiol.13, 995–999 (2002).
   PubMedGoogle Scholar
• Takayasu K, Arii S, Ikai I et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology131, 461–464 (2006).
   PubMed Web of Science ®Google Scholar
• Bronowicki JP, Vetter D, Dumas F et al. Transcatheter oily chemoembolization for hepatocellular carcinoma: a 4-year study of 127 French patients. Cancer74, 16–24 (1994).
   PubMedGoogle Scholar
• Brown DB, Pilgram KT, Darcy MD et al. Hepatic arterial chemoembolization for hepatocellular carcinoma: comparison of survival rates with different embolic agents. J. Vasc. Interv. Radiol.16, 1661–1661 (2005).
   PubMedGoogle Scholar
• Chen MS, Li J-Q, Zhang Y-Q et al. High-dose iodized oil transcatheter arterial chemoembolization for patients with large hepatocellular carcinoma. World J. Gastroenterol.8(1), 74–78 (2002).
   PubMed Web of Science ®Google Scholar
• Park KW, Park JW, Cho SH et al. Survival analysis for patients with hepatocellular carcinoma according to stage, liver function and treatment modalities]. Korean J. Hepatol.12(1), 41–54 (2006).
   PubMedGoogle Scholar
• Ha BY, Ahmed AD, Sze DY et al. Long-term survival of patients with unresectable hepatocellular carcinoma treated with transcatheter arterial chemoinfusion. Aliment. Pharmacol. Ther.26, 839–846 (2007).
   PubMedGoogle Scholar
• Chang JM, Tzeng WS, Pan HB et al. Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma. A randomized controlled study. Cancer74, 2449–2442 (1994).
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V et al. SHARP Investigators Study Group.Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med.359(4), 378–390 (2008).
   PubMed Web of Science ®Google Scholar
• Simpson D, Keating GM. Sorafenib: in hepatocellular carcinoma. Drugs68(2), 251–258 (2008).
   PubMed Web of Science ®Google Scholar
• Cheng BQ, Jia CQ, Liu CT et al. Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial. JAMA299(14), 1669–1677 (2008).
   PubMed Web of Science ®Google Scholar
• Veltri A, Moretto P, Doriguzzi A et al. Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC). Eur Radiol.16(3), 661–669 (2006).
   PubMed Web of Science ®Google Scholar
• Lencioni R, Crocetti L, Petruzzi P et al. Doxorubicin-eluting bead-enhanced radiofrequency ablation of hepatocellular carcinoma: a pilot clinical study. J. Hepatol.49(2), 217–222 (2008).
   PubMed Web of Science ®Google Scholar
• Ramsey DE, Kernagis LY, Soulen MC et al. Chemoembolization of hepatocellular carcinoma. J. Vasc. Interv. Radiol.13(Suppl.), S211–S221 (2002).
   PubMed Web of Science ®Google Scholar
• Kim W, Clark TW, Baum RA, Soulen MC. Risk factors for liver abscess formation after hepatic chemoembolization. J. Vasc. Interv. Radiol.12, 965–969 (2001).
   PubMed Web of Science ®Google Scholar
• Chung JW, Park JH, Han JK et al. Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization. Radiology198, 33–40 (1996).
   PubMed Web of Science ®Google Scholar
• Wigmore SJ, Redhead DN, Thomson BN et al. Postchemoembolization syndrome: tumour necrosis or hepatocyte injury? Br. J. Cancer89, 1423–1422 (2003).
   PubMedGoogle Scholar